BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

...are immeasurable. The many companies he formed (Alza, Affymax, Alexza, Affymetrix, Dynapol, DNAX, Symyx, Maxygen, SurroMed...
BioCentury | Jan 24, 2005
Company News

PPD, SurroMed deal

...PPDI will acquire SurroMed's biomarker business. In exchange, PPDI will cancel the SurroMed preferred shares it...
...shares it received in 2002 and 2003. In addition, PPDI will assume $3.4 million of SurroMed's...
...PPDI also will guarantee repayment of up to $1.5 million of a SurroMed bank loan. SurroMed...
BioCentury | Nov 1, 2004
Strategy

Biomarker deals

...discover pain-related proteomic biomarkers 8/18/03 Wyeth Study biomarkers to compare Wyeth compounds for inflammation 7/21/03 SurroMed...
BioCentury | Nov 1, 2004
Strategy

Biomarkers missing the mark(et)

...to create an independent service-based biomarker company," agreed Gordon Ringold, co-founder, chairman and CEO of SurroMed Inc....
...of has agreed to give royalties on a product in a deal for biomarkers." Although SurroMed...
...short term, the company is transitioning toward developing diagnostics for its own account. In 2002, SurroMed...
BioCentury | Oct 25, 2004
Company News

Biocon board of directors update

...Bala Manian, chairman and co-founder of Reametrix Inc., and co-founder of Quantum Dot Corp. and Surromed...
BioCentury | Jul 12, 2004
Company News

SurroMed, Merck deal

...Under an expansion of an existing deal, SurroMed will do proteomic analysis using its biomarker discovery...
...preclinical samples provided by MRK to identify potential biological markers. Financial terms were not disclosed. SurroMed Inc....
BioCentury | May 3, 2004
Company News

SurroMed management update

SurroMed Inc. , Mountain View, Calif. Business: Pharmacogenetics Promoted: Christopher Becker to VP from director of chemistry; and William Leschensky to VP from director of IP WIR Staff...
BioCentury | Apr 12, 2004
Strategy

Biocon's bellwether role

...identify novel biomarkers of progression to overt Type II diabetes. The study was conducted for SurroMed Inc....
BioCentury | Mar 15, 2004
Company News

Biogen Idec, SurroMed deal

...The companies extended their 2002 deal, under which SurroMed is characterizing the responses of multiple sclerosis...
...BIIB's Avonex interferon beta-1a (see BioCentury, June 24, 2002). Biogen Idec Inc. (BIIB), Cambridge, Mass. SurroMed Inc....
BioCentury | Dec 15, 2003
Company News

Ingenuity, SurroMed deal

...therapeutically relevant protein networks derived from experimental results. Ingenuity Systems Inc. , Mountain View, Calif. SurroMed Inc....
Items per page:
1 - 10 of 37
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

...are immeasurable. The many companies he formed (Alza, Affymax, Alexza, Affymetrix, Dynapol, DNAX, Symyx, Maxygen, SurroMed...
BioCentury | Jan 24, 2005
Company News

PPD, SurroMed deal

...PPDI will acquire SurroMed's biomarker business. In exchange, PPDI will cancel the SurroMed preferred shares it...
...shares it received in 2002 and 2003. In addition, PPDI will assume $3.4 million of SurroMed's...
...PPDI also will guarantee repayment of up to $1.5 million of a SurroMed bank loan. SurroMed...
BioCentury | Nov 1, 2004
Strategy

Biomarker deals

...discover pain-related proteomic biomarkers 8/18/03 Wyeth Study biomarkers to compare Wyeth compounds for inflammation 7/21/03 SurroMed...
BioCentury | Nov 1, 2004
Strategy

Biomarkers missing the mark(et)

...to create an independent service-based biomarker company," agreed Gordon Ringold, co-founder, chairman and CEO of SurroMed Inc....
...of has agreed to give royalties on a product in a deal for biomarkers." Although SurroMed...
...short term, the company is transitioning toward developing diagnostics for its own account. In 2002, SurroMed...
BioCentury | Oct 25, 2004
Company News

Biocon board of directors update

...Bala Manian, chairman and co-founder of Reametrix Inc., and co-founder of Quantum Dot Corp. and Surromed...
BioCentury | Jul 12, 2004
Company News

SurroMed, Merck deal

...Under an expansion of an existing deal, SurroMed will do proteomic analysis using its biomarker discovery...
...preclinical samples provided by MRK to identify potential biological markers. Financial terms were not disclosed. SurroMed Inc....
BioCentury | May 3, 2004
Company News

SurroMed management update

SurroMed Inc. , Mountain View, Calif. Business: Pharmacogenetics Promoted: Christopher Becker to VP from director of chemistry; and William Leschensky to VP from director of IP WIR Staff...
BioCentury | Apr 12, 2004
Strategy

Biocon's bellwether role

...identify novel biomarkers of progression to overt Type II diabetes. The study was conducted for SurroMed Inc....
BioCentury | Mar 15, 2004
Company News

Biogen Idec, SurroMed deal

...The companies extended their 2002 deal, under which SurroMed is characterizing the responses of multiple sclerosis...
...BIIB's Avonex interferon beta-1a (see BioCentury, June 24, 2002). Biogen Idec Inc. (BIIB), Cambridge, Mass. SurroMed Inc....
BioCentury | Dec 15, 2003
Company News

Ingenuity, SurroMed deal

...therapeutically relevant protein networks derived from experimental results. Ingenuity Systems Inc. , Mountain View, Calif. SurroMed Inc....
Items per page:
1 - 10 of 37